Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH)-possible therapeutic...

Area of Science:

• Cardiovascular Medicine
• Molecular Cardiology
• Pharmacology

Background:

• Left ventricular hypertrophy (LVH) is a maladaptive cardiac remodeling in response to systemic hypertension (SH).
• LVH increases the risk of cardiovascular morbidity and mortality.
• Vasoactive peptides, oxidative stress, and specific signaling pathways are implicated in SH-induced LVH.

Purpose of the Study:

• To explore novel therapeutic strategies for preventing or reversing cardiac complications of SH-induced LVH.
• To investigate the potential of targeting specific humoral factors and biochemical pathways involved in cardiac hypertrophy.

Main Methods:

• Review of experimental studies in animal models investigating humoral factors and their impact on cardiac hypertrophy.
• Analysis of the roles of angiotensin II, endothelin-1, norepinephrine, Rho/Ras proteins, oxidative stress, heat shock proteins, calcineurin, and kinases in LVH.

Main Results:

• Antihypertensive treatments often fail to prevent or reverse LVH despite reducing blood pressure.
• Certain humoral factors can suppress biochemical hypertrophic responses, offering cardioprotection independently of antihypertensive effects.
• Cyclosporine-A, scutellarin, and spironolactone show potential as antihypertrophic agents.

Conclusions:

• Novel therapeutic approaches targeting humoral factors and biochemical pathways are needed to combat LVH.
• Developing drugs based on identified antihypertrophic substances could offer a new strategy against cardiovascular complications of hypertension.